US panel puts the spotlight on pivotal Covid vaccine readouts
Moderna battles Pfizer/Biontech to generate the first pivotal study data for a Covid-19 vaccine.
Clinical setback lays bare Vertex’s weakness
As the company is punished for its failure to diversify, could it be forced into making an acquisition?
Ionis joins the inhaled cystic fibrosis therapy race
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
J&J pause adds to adenovirus vaccine doubts
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Thinking the unthinkable on Covid vaccine approvals
With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?
Go or no go? Vaccine panel upstages US approval decisions
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
J&J and Novavax push Covid-19 vaccine candidates into late-stage testing
Five candidates are now in phase III trials in the West, as Pfizer approaches its first interim readout.
Covid vaccine developers face nervous wait
More details on an adverse event in a trial of Astrazeneca's AZD1222 will be needed to assess the fallout for other vaccine developers.
